March 3, 2011 – The U.S. Food and Drug Administration (FDA) has cleared a whole-body positron emission tomography (PET) application. Xpress.PET, by UltraSpect, enables reduced dose and acquisition time without compromising image quality.
The benefits of application, which is based on the company’s Wide-Beam Reconstruction (WBR) technology in whole body PET/CT scanning include:
• Reduced PET acquisition time to 15 minutes for a whole body Fludeoxyglucose (FDG) PET/CT scan
• Reduced injection dose, minimizing patient radiation exposure
• Improved image signal to noise ratio
• Enhanced patient throughput and department productivity
• Greater patient tolerance and comfort during scanning
“With new Xpress.PET users can shorten scan times or reduce FDG dose up to 40 percent--reducing a typical PET scan to 15 minutes for most patients instead of 24 minutes,” said Mack Burris, R.T., clinical product specialist for UltraSpect. “Alternatively, an FDG dose of a normal patient can be reduced to 10 mCi from 15 mCi. The initial product will be released for the GE Discovery LS PET/CT system and will be adapted to other PET/CT devices shortly, and will make the performance of older PET/CT scanners comparable to newer models.”
WBR products accurately compensate for the physical effects in data acquisition, such as resolution, attenuation and scatter, while controlling the noise level. Physicians have the same clinical information as typical PET/CT technology in shorter time periods or with lower injection dose, minimizing radiation exposure to patients and staff, while enhancing efficiency and patient throughput.
For more information: www.ultraspect.com
July 25, 2024 
